By Amber Roman
Sep 23, 2024, 5:51 PM EDT
In a groundbreaking move in the fight against seasonal flu, the US Food and Drug Administration (FDA) has approved the use of a nasal spray flu vaccine for self-administration. This is the first time that such a vaccine has been given the green light to be administered by patients or their caregivers themselves, without the direct intervention of a health professional. The announcement was made last Friday, and the vaccine in question, FluMist, developed by the pharmaceutical company AstraZeneca, will be available from next fall.
FluMist, which was first approved in 2003, has traditionally been administered by physicians or other health care professionals. Now, with the new approval, anyone in the United States will be able to obtain it through online pharmacies, after undergoing a medical evaluation that will determine their suitability for the treatment. This advancement could transform the way people access flu vaccination, making the process easier and removing some of the barriers that have historically limited vaccination coverage.
One of the highlights of this decision is the focus on convenience for patients. Peter Marks, one of the FDA’s top officials, highlighted the benefits that this new modality will bring to both individuals and families. According to Marks, the possibility of self-administering a seasonal flu vaccine adds a layer of flexibility and accessibility that can make it easier for more people to choose to get vaccinated. This is especially relevant in a context where flu vaccination rates have been trending downwards.
Anyone 18 or older can self-administer FluMist or help someone else do so, as long as they are within the age range for the vaccine, which is approved for people ages 2 to 49. This means that families can also take a more active role in protecting their younger members from the flu, which could be especially beneficial during times of high viral transmission.
FluMist is based on a weakened version of the influenza virus, which sets it apart from traditional injectable vaccines that often contain dead or inactive viruses. This weakened version of the virus does not cause illness, but it does stimulate the immune system to be ready to fight off the real flu if a person is ever exposed. This technology has been proven safe and effective over the years, but its new self-administered form could make it even more popular among those who prefer to avoid needles.
Seasonal influenza is one of the most common diseases worldwide and, according to the World Health Organization (WHO), affects approximately one billion people each year, of whom between 290,000 and 650,000 die as a result of complications associated with the disease. In this context, an accessible and easy-to-administer vaccine can make a crucial difference in the fight against influenza, especially in terms of preventing the spread of the virus in communities.
Although flu vaccination has been a major public health tool for decades, vaccination rates have seen a decline since the 2020-21 season, with a 3.3% decrease. This decline has raised concerns among health experts, who are looking for new ways to motivate people to get vaccinated more consistently. A recent survey suggests that at-home vaccination options, like the one now offered by FluMist, could be key to reversing this trend and increasing vaccine acceptance in the general population.
By next fall, FluMist is expected to be available to millions of people across the country, providing a more flexible and convenient option for flu protection. This initiative not only aims to improve vaccination rates, but also to make flu protection more accessible to those who, for various reasons, have chosen not to get vaccinated in the past. Access through online pharmacies, elimination of the need for a needle, and ease of use are some of the factors that could drive adoption of this new public health tool.
In conclusion, the approval of self-administration of FluMist marks a significant shift in the influenza vaccination strategy in the United States, providing a more accessible and convenient option for millions of people, with the hope that this will translate into greater protection against this seasonal disease.
Continue reading:
- Reducing sugar and starch intake improves irritable bowel syndrome
- Loneliness doesn’t cause as many diseases as we thought: study
- Nearly 40 million people could die from superbug crisis by 2050